scholarly journals Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET

Theranostics ◽  
2020 ◽  
Vol 10 (14) ◽  
pp. 6082-6094 ◽  
Author(s):  
Daniela A. Ferraro ◽  
Jan H. Rüschoff ◽  
Urs J. Muehlematter ◽  
Benedikt Kranzbühler ◽  
Julian Müller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Detection Rate ◽  
Expression Patterns ◽  
Cancer Tissue ◽  
Primary Prostate Cancer ◽  
Prostate Cancer Tissue ◽  
Psma Expression

Expression Patterns of ERα, ERβ, AR, SIRT1, SIRT2, and SIRT3 in Prostate Cancer Tissue and Normal Prostate Tissue

2021 ◽  
Vol 41 (3) ◽  
pp. 1377-1386
Author(s):  
JAE HWI CHOI ◽  
SEE MIN CHOI ◽  
SIN WOO LEE ◽  
SEONG UK JEH ◽  
JAE SEOG HYUN ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Expression Patterns ◽  
Prostate Tissue ◽  
Cancer Tissue ◽  
Normal Prostate ◽  
Prostate Cancer Tissue ◽  
Normal Prostate Tissue

scholarly journals Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence

2011 ◽  
Vol 102 (8) ◽  
pp. 1576-1581 ◽  
Author(s):  
Hitoshi Ishiguro ◽  
Kazunori Akimoto ◽  
Yoji Nagashima ◽  
Eriko Kagawa ◽  
Takeshi Sasaki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Cancer Tissue ◽  
Prostate Cancer Tissue

Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 166-166
Author(s):  
Taylor Ryan McFarland ◽  
Roberto Nussenzveig ◽  
Umang Swami ◽  
Nicolas Sayegh ◽  
Adam Kessel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Tissue ◽  
Early Event ◽  
Cancer Tissue ◽  
Copy Number Loss ◽  
Genomic Profiling ◽  
Castration Resistant Prostate Cancer ◽  
Primary Prostate Cancer ◽  
Prostate Cancer Tissue ◽  
Comprehensive Genomic Profiling

166 Background: Both olaparib and rucaparib have recently been approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) with BRCA1/2 mutations (BRCAm). In the PROFOUND trial, 36.9% of men had either no tissue or tissue that was inadequate for genomic profiling (PMID: 32343890). A recent report suggests BRCAm may be an early event in the evolution of prostate cancer (PMID: 29662167). This suggests comprehensive genomic profiling (CGP) of primary prostate tissue may suffice to guide treatment selection, even years after tissue collection. Herein, we investigate the ontogeny of BRCAm by comparing CGP of matched primary prostate cancer tissue to CGP of cfDNA. Methods: Eligibility criteria included men diagnosed with metastatic prostate cancer that had matched CGP of both primary prostate cancer tissue and cfDNA. Genomic profiling was performed by CLIA certified laboratories. Only somatic mutations detectable by both platforms were used for concordance analysis. Results: We identified 198 patients that had matched CGP of primary prostate tissue and cfDNA. Thirteen men had a pathogenic BRCAm in at least one test. Of these 13 positive test for BRCAm, 2 were rearrangements, 1 copy number loss, and 5 were germline mutations. Both platforms tend to filter out germline alterations therefore, they were not included in the estimation of concordance. Overall somatic BRCAm concordance between primary prostate tissue and cfDNA was 196/198 (98%). Notably, no new BRCAm were identified in cfDNA with a median difference of 23.62 (0.1 - 232.2) months between prostate cancer tissue and cfDNA collection. Conclusions: There were no BRCAm detected only in cfDNA, suggesting that BRCAm is an early event in the ontogeny of prostate cancer. Based on this, it is unlikely that delaying sequencing would benefit patients with advanced prostate cancer. In the event that tissue is unavailable or inadequate for CGP, profiling of cfDNA is a valuable alternative for detection of BRCAm.

Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs

2006 ◽  
Vol 236 (1) ◽  
pp. 95-104 ◽  
Author(s):  
Susanne Fuessel ◽  
Bernd Weigle ◽  
Uta Schmidt ◽  
Gustavo Baretton ◽  
Rainer Koch ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
G Protein ◽  
Cancer Tissue ◽  
G Protein Coupled Receptor ◽  
Transcript Quantification ◽  
Primary Prostate Cancer ◽  
Prostate Cancer Tissue ◽  
G Protein Coupled

PET/CT WITH 68GA-PSMA-11 IN DETECTION OF PRIMARY TUMOR AND RECURRENCE OF PROSTATE CANCER

2018 ◽  
Vol 64 (6) ◽  
pp. 799-804
Author(s):  
Darya Ryzhkova ◽  
M. Poyda
Keyword(s):  
Prostate Cancer ◽  
Primary Tumor ◽  
Biochemical Recurrence ◽  
Whole Body ◽  
Negative Results ◽  
Primary Prostate Cancer ◽  
Pet Ct ◽  
The Relationship ◽  
Positive Results ◽  
T Category

Purpose: To study the diagnostic value of PET-CT with 68Ga-PSMA-11 in the diagnosis of a primary prostate cancer, preoperative staging, and the detection of recurrence of prostate cancer (PCa). Methods: 28 patients aged 64.7 ± 8.74 years were included. 10 patients primary prostate cancer, and 18 patients with biochemical recurrence of the disease after radical treatment were examined. All patients underwent PET-CT with 68Ga-PSMA-11 according the whole body protocol. Interpretation of images was performed visually and quantitatively by calculation of SUL max. Results: High focal or diffuse 68Ga-PSMA-11 uptake was found in prostate parenchyma in patients with primary prostate cancer. Additionally metastases in regional lymph nodes were diagnosed in 4 patients and bone metastases were found in one patient. The correlation between 68Ga-PSMA-11 uptake level and Gleason index in the primary tumor (R Spearmen = 0.25, p = 0.57) was not observed. PET-positive results were obtained in 14 patients and PET-negative results in 4 patients with biochemical recurrence of PCa. The relationship between the frequency of PET-positive results and Gleason index was not revealed (R Spearmen = 0.2, p = 0.39). We found a weak but significant correlation between the frequency of PET-positive results and the prostate tumor stage according to the T category (R Spearmen = 0.49, p = 0.049). In patients with low values of PSA (less than 1.0 ng/ml) in 4 out of 9 cases, PET-negative results were obtained. In patients with PSA level more than 1.0 ng/ml PET-positive results were obtained in all cases. Conclusions: PET/CT with 68Ga-PSMA-11 allows to diagnose the primary prostate cancer, to establish the stage of the disease in categories N and M, and also to determine the localization and dissemination of the tumor in patients with biochemical recurrence of prostate cancer. The relationship between 68Ga-PSMA-11 uptake in primary tumor and Gleason index was not found. The probability of obtaining PET-positive results in cases of biochemical recurrence is affected by a PSA level above 1 ng/ml and a high stage of the disease according to the T category (T3-T4).

Sign in / Sign up

Export Citation Format

Share Document